CBD Market 'Surges' As FDA Delays Setting Regulatory Policy – NPA

FDA should formalize its internal policy on CBD enforcement or create a pathway to make it compliant for use in supplements, says NPA President Daniel Fabricant. NPA and PCPC submitted comments on FDA request for input on agency's action at ongoing United Nations meeting on drug policy.

Cannibis

More from Regulation

More from Policy & Regulation